Physician profile
Taylor Graham
NPI 1861018475
$1,314.86
in general payments reported to CMS, 2019-2025
18 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $339 · 2023: $174 · 2024: $266 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $214.19 | 2022-2025 | Briviact, Rystiggo, Nayzilam |
| Neurocrine Biosciences, INC. | $181.69 | 2023-2024 | Ingrezza, Ongentys |
| Eisai INC. | $146.83 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $132.54 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $114.62 | 2022 | |
| Impel Pharmaceuticals INC. | $96.67 | 2023 | Trudhesa |
| Livanova USA, INC. | $94.93 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Tanabe Pharma America, INC. | $50.45 | 2025 | Radicava |
| Abbvie INC. | $44.76 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $42.41 | 2022 | |
| Alnylam Pharmaceuticals INC. | $35.13 | 2023-2025 | Amvuttra, Onpattro |
| Takeda Pharmaceuticals U.S.A., INC. | $32.28 | 2025 | Hyqvia |
| Genentech USA, INC. | $27.85 | 2025 | Ocrevus Zunovo |
| Neurelis, INC. | $24.91 | 2025 | Valtoco |
| Xeris Pharmaceuticals, INC. | $22.03 | 2025 | Keveyis |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.38 | 2025 | Symbravo |
| Lilly USA, LLC | $17.15 | 2024 | Emgality |
| Aucta Pharmaceuticals, INC. | $15.04 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.